Payment overview · 2025
General Payments
$138.73
8 reported records · 5 companies
Healthcare provider profile · identity verified
Clara Lee
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · SEBASTIAN, FL · NPI 1346735727
Verified facts
What the public records show
CMS Open Payments records show Clara Lee received $138.73 in general payments during 2025 across 8 reported records.
Lilly USA, LLC accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta, Xifaxan.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.01 | 38.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.59 | 24.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.89 | 13.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.66 | 12.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.58 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $138.73 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.01 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 105 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 520 | 178 |
| Losartan Potassium | Losartan Potassium | 414 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 103 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 323 | 172 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 290 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 288 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 275 | 82 |
| Prednisone | Prednisone | 275 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 93 |
| Gabapentin | Gabapentin | 239 | 75 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 235 | 88 |
| Trazodone Hcl | Trazodone Hcl | 192 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 185 | 56 |
| Omeprazole | Omeprazole | 180 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 61 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 169 | 43 |
| Lisinopril | Lisinopril | 165 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 154 | 61 |
| Metformin Hcl | Metformin Hcl | 153 | 47 |
| Glipizide Er | Glipizide | 149 | 34 |
| Azithromycin | Azithromycin | 146 | 99 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 57 |
| Metformin Hcl Er | Metformin Hcl | 135 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 46 |
| Bupropion Xl | Bupropion Hcl | 117 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 29 |
| Furosemide | Furosemide | 115 | 36 |
| Levofloxacin | Levofloxacin | 115 | 69 |
| Buspirone Hcl | Buspirone Hcl | 114 | 38 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 114 | 79 |
| Donepezil Hcl | Donepezil Hcl | 110 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 22 |
| Ezetimibe | Ezetimibe | 103 | 34 |
| Meloxicam | Meloxicam | 103 | 32 |
| Eliquis | Apixaban | 102 | 24 |
| Fluconazole | Fluconazole | 98 | 61 |
| Naproxen | Naproxen | 89 | 38 |
| Allopurinol | Allopurinol | 86 | 26 |
| Celecoxib | Celecoxib | 85 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 19 |
| Cephalexin | Cephalexin | 82 | 55 |
| Lansoprazole | Lansoprazole | 81 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 79 | 25 |
| Topiramate | Topiramate | 76 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 75 | 53 |
| Montelukast Sodium | Montelukast Sodium | 71 | 31 |
| Spironolactone | Spironolactone | 71 | 27 |
| Methotrexate | Methotrexate Sodium | 70 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 67 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 65 | 19 |
| Alendronate Sodium | Alendronate Sodium | 64 | 12 |
| Ozempic | Semaglutide | 64 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 23 |
| Mirtazapine | Mirtazapine | 62 | 25 |
| Torsemide | Torsemide | 62 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 19 |
| Atenolol | Atenolol | 59 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 29 |
| Pentoxifylline | Pentoxifylline | 57 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 34 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 53 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 15 |
| Chlorthalidone | Chlorthalidone | 49 | 16 |
| Potassium Chloride | Potassium Chloride | 49 | 14 |
| Famotidine | Famotidine | 48 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 15 |
| Mupirocin | Mupirocin | 46 | 24 |
| Doxepin Hcl | Doxepin Hcl | 44 | 14 |
| Finasteride | Finasteride | 44 | 14 |
| Jardiance | Empagliflozin | 44 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 11 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 43 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Folic Acid | Folic Acid | 42 | 16 |
| Sertraline Hcl | Sertraline Hcl | 42 | 14 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 17 |
| Linzess | Linaclotide | 40 | 12 |
| Valsartan | Valsartan | 40 | 16 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Glipizide | Glipizide | 37 | 13 |
| Memantine Hcl | Memantine Hcl | 36 | 12 |
| Captopril | Captopril | 35 | 15 |
| Carvedilol | Carvedilol | 35 | 13 |
| Estradiol | Estradiol | 35 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 15 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 15 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | 11 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | 11 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 23 |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 16 |
| Calcitriol | Calcitriol | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 11 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Colchicine | Colchicine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | 11 |
| Ramipril | Ramipril | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $138.73 · 8 records | Lilly USA, LLC | MOUNJARO, OTEZLA, Ohtuvayre, REPATHA, TRELEGY ELLIPTA, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error